GNLX vs REPL
GNLX: Genelux is a clinical-stage biotechnology company developing off-the-shelf, oncolytic vaccinia virus therapies designed to re-sensitize resistant solid tumors to conventional treatments. REPL: Replimune is an oncolytic immunotherapy company developing viral-based therapies that turn "cold" tumors "hot" to induce a potent, systemic immune response against cancer.
Side-by-side fundamentals
| Metric | GNLX | REPL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.50 | $11.42 | |
| Market cap as of 2026-08-11 (share count; price 2026-10-20) | $113M | $1.1B | |
| Net margin FY2025, SEC XBRL | -401812.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -415175.0% | n/a | |
| ROE | -278.5% | -188.9% | REPL higher |
| ROA | -168.9% | -94.4% | REPL higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.80 | |
| Revenue CAGR (3y) SEC XBRL | -91.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.40 | 0.63 | |
| 1-year return as of 2026-10-20 close | -61.6% | +27.7% | REPL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.